Abstract P4-12-09: Results from a phase 2a study of trastuzumab emtansine, paclitaxel, and pertuzumab in patients with HER2-positive metastatic breast cancer

MLA

Ian E. Krop, et al. “Abstract P4-12-09: Results from a Phase 2a Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients with HER2-Positive Metastatic Breast Cancer.” Cancer Research, vol. 73, Dec. 2013, pp. P4-12. EBSCOhost, https://doi.org/10.1158/0008-5472.sabcs13-p4-12-09.

APA

Ian E. Krop, Mark D. Pegram, Shanu Modi, PL LoRusso, BL Althaus, Anthony D. Elias, D Ipe, & Ellie Guardino. (2013). Abstract P4-12-09: Results from a phase 2a study of trastuzumab emtansine, paclitaxel, and pertuzumab in patients with HER2-positive metastatic breast cancer. Cancer Research, 73, P4-12. https://doi.org/10.1158/0008-5472.sabcs13-p4-12-09

Chicago

Ian E. Krop, Mark D. Pegram, Shanu Modi, PL LoRusso, BL Althaus, Anthony D. Elias, D Ipe, and Ellie Guardino. 2013. “Abstract P4-12-09: Results from a Phase 2a Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients with HER2-Positive Metastatic Breast Cancer.” Cancer Research 73 (December): P4-12. doi:10.1158/0008-5472.sabcs13-p4-12-09.